Crossmark

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Crossref DOI link: https://doi.org/10.1186/s12954-021-00500-9

Published Online: 2021-05-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Palis, Heather https://orcid.org/0000-0002-8570-5717
MacDonald, Scott

Jun, Jennifer

Oviedo-Joekes, Eugenia
Funding

Funding for this research was provided by:

Providence Health Care (PHC/VCH Knowledge Translation Challenge)
License Information

Text and Data Mining valid from 2021-05-20

Version of Record valid from 2021-05-20
More Information

Article History

Received: 3 November 2020

Accepted: 29 April 2021

First Online: 20 May 2021

Declarations

:

: Informed consent was obtained from the participant, who approved the final version of the case profile and confirmed that it accurately reflected his experience. As per communication with the University of British Columbia Research Ethics Board, ethical approval was not required.

: Not applicable (No personal identifier is included).

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below